N. Peled Et Al. , "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients," Lung Cancer , vol.148, pp.48-54, 2020
Peled, N. Et Al. 2020. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer , vol.148 , 48-54.
Peled, N., Gillis, R., Kilickap, S., Froesch, P., Orlov, S., Filippova, E., ... Demirci, U.(2020). GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer , vol.148, 48-54.
Peled, Nir Et Al. "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients," Lung Cancer , vol.148, 48-54, 2020
Peled, Nir Et Al. "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients." Lung Cancer , vol.148, pp.48-54, 2020
Peled, N. Et Al. (2020) . "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients." Lung Cancer , vol.148, pp.48-54.
@article{article, author={Nir Peled Et Al. }, title={GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients}, journal={Lung Cancer}, year=2020, pages={48-54} }